Extended Data Fig. 7: Lack of correlation between PD1 expression and clinical response in patients treated with anti-TIGIT antibody.
a. PD-1 expression in bone marrow CD4 and CD8 cell subsets from biospecimens obtained from responding (Resp) or non-responding (NR) patients before (PreRx) after first (C1) or second cycle (C2) of therapy with anti-TIGIT antibody. Data points represent biologically independent samples (TIGIT Resp PreRx: n = 3, TIGIT Resp C1: n = 2, TIGIT Resp C2: n = 3; TIGIT NR PreRx: n = 3; TIGIT NR C1: n = 1, TIGIT NR C2: n = 2). No differences were seen in the expression of PD1 between responders and non-responders. Statistical test compares post Rx (C1 + C2) specimens from responders (n = 5) and non-responders (n = 3) to anti-TIGIT therapy, 2-tailed Mann Whitney. b. PD-1 expression in blood CD4 and CD8 cell subsets from biospecimens obtained from responding (Resp) or non-responding (NR) patients before (PreRx) after first (C1) or second cycle (C2) of therapy with anti-TIGIT antibody. Data points represent biologically independent samples (TIGIT Resp PreRx: n = 4, TIGIT Resp C1: n = 7, TIGIT Resp C2: n = 4; TIGIT NR Pre Rx: n = 4; TIGIT NR C1: n = 9, TIGIT NR C2: n = 2). No differences were seen in the expression of PD1 between responders and non-responders. Statistical test compares post Rx (C1 + C2) specimens from responders (n = 11) and non-responders (n = 11) to anti-TIGIT therapy, 2-tailed Mann Whitney. Box plots represent median with Q1-Q3 and error bars as min-max. MMI: median metal intensity.
